Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LEG files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsLeggett & Platt clears U.S. antitrust review for Somnigroup merger, targets year-end close
Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
The 30-day HSR Act waiting period expired June 3 without objection, clearing the U.S. antitrust hurdle for Leggett & Platt's acquisition by Somnigroup.
Item 8.01 verify on EDGAR → -
high
Transaction still requires shareholder approval and regulatory clearances in five foreign jurisdictions (Canada, EU, UK, South Korea, Austria) before the targeted year-end 2026 close.
Item 8.01 verify on EDGAR → -
medium
Deal remains subject to SEC registration statement effectiveness and no material adverse effect occurring at either company since signing.
Item 8.01 verify on EDGAR →
Summary
Leggett & Platt has cleared a key regulatory milestone in its pending acquisition by Somnigroup, with the U.S. antitrust waiting period expiring without challenge on June 3. This removes one hurdle but leaves several significant conditions outstanding before the deal can close by year-end 2026 as planned.
Shareholders should care because the transaction's completion now hinges on a shareholder vote and approvals from five international competition authorities spanning three continents. Multi-jurisdictional reviews introduce execution risk and potential delays, particularly in the EU where merger reviews can extend beyond initial timelines.
The deal also requires that neither company experiences a material adverse effect between signing and closing. Watch for the proxy statement filing and shareholder meeting date, which will provide the next concrete milestone. Also monitor for any announcements regarding foreign regulatory filings or requests for additional information, which could signal timing pressure on the year-end target.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 3, 2026 at 11:59 p.m., Eastern Time, the required 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), expired.
The mandatory U.S. antitrust review period for Leggett & Platt's merger with Somnigroup has concluded without objection. This removes one regulatory hurdle, though the deal still requires shareholder approval and clearances from Canada, the EU, UK, South Korea, and Austria before closing.
Added in current filing · verify on EDGAR →
The Company expects the transaction to close by year-end 2026, subject to the fulfillment or waiver of certain conditions, including, among others, (i) the adoption of the Merger Agreement and approval of the Merger by the shareholders of the Company, (ii) the receipt of all clearances, consents and approvals under certain specified competition laws in Canada, the European Union, the United Kingdom, and the Republic of Korea, as well as under applicable foreign investment laws in Austria; (iii) the effectiveness of a registration statement on Form S-4 to be filed by Parent with the Securities and Exchange Commission (“SEC”) and the absence of any stop order or pending proceeding with respect thereto; and (iv) the absence of any material adverse effect with respect to Parent and the Company since the date of the Merger Agreement.
Leggett & Platt targets a year-end 2026 close for its acquisition by Somnigroup. Key remaining steps include a shareholder vote, international regulatory approvals across five jurisdictions, SEC registration effectiveness, and no material adverse changes. The multi-jurisdictional review process introduces execution risk and potential timing delays.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify